CNBC’s Jim Cramer on Thursday thought it worthwhile to review ten stocks that led the Dow Jones Industrial Average over the ...

But this week, the stock jumped again after Amgen issued a strong financial update Tuesday. Its rise helped push up the S&P ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Amgen Inc (NASDAQ:AMGN) reported better-than-expected fourth-quarter results on Tuesday, but its shares fell 1.5% in premarket trading Wednesday as the company's profit outlook for 2025 fell short of ...

The company said the agency's hold was "not related to the drug,” dubbed AMG 513, and that discussions were underway to ...